Taysha Gene Therapies's Total Assets for the quarter that ended in Dec. 2023 was $172.73 Mil.
During the past 12 months, Taysha Gene Therapies's average Total Assets Growth Rate was -25.00% per year.
During the past 3 years, the average Total Assets Growth Rate was 55.70% per year.
During the past 5 years, Taysha Gene Therapies's highest 3-Year average Total Assets Growth Rate was 1267.90%. The lowest was 55.70%. And the median was 661.80%.
Taysha Gene Therapies Total Assets Historical Data
The historical data trend for Taysha Gene Therapies's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Taysha Gene Therapies's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taysha Gene Therapies (NAS:TSHA) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Taysha Gene Therapies's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Taysha Gene Therapies Total Assets Related Terms
Thank you for viewing the detailed overview of Taysha Gene Therapies's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Taysha Gene Therapies (Taysha Gene Therapies) Business Description
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSHA has been successfully added to your 